{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477351069
| IUPAC_name = [(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid
| image = Atagabalin.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 223445-75-8
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 593430
| PubChem = 9794485
| ATC_prefix = none
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = JT7957Q2FB
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 7970252

<!--Chemical data-->
| C=10 | H=19 | N=1 | O=2 
| molecular_weight = 185.263 g/mol
| smiles = C[C@H]1CC(C[C@@H]1C)(CC(=O)O)CN
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H19NO2/c1-7-3-10(6-11,4-8(7)2)5-9(12)13/h7-8H,3-6,11H2,1-2H3,(H,12,13)/t7-,8-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IUVMAUQEZFTTFB-YUMQZZPRSA-N
}}

'''Atagabalin''' ('''PD-0200,390''') is a drug developed by [[Pfizer]] and related to [[gabapentin]], which similarly binds to the α<sub>2</sub>δ [[calcium channel]]s ([[CACNA2D1|1]] and [[CACNA2D2|2]]).<ref name="pmid20005103">{{cite journal |vauthors=Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC |title=Synthesis and in vivo evaluation of bicyclic gababutins |journal=Bioorganic & Medicinal Chemistry Letters |volume=20 |issue=2 |pages=461–4 |date=January 2010 |pmid=20005103 |doi=10.1016/j.bmcl.2009.11.118 |url=}}</ref> It was under development as a treatment for [[insomnia]],<ref name="pmid19694735">{{cite journal |vauthors=Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G |title=Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit |journal=British Journal of Clinical Pharmacology |volume=68 |issue=2 |pages=174–80 |date=August 2009 |pmid=19694735 |pmc=2767279 |doi=10.1111/j.1365-2125.2009.03444.x |url=}}</ref><ref name="pmid21664606">{{cite journal |vauthors=Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA |title=Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology |journal=Brain Research |volume= 1401|issue= |pages= 1–9|date=May 2011 |pmid=21664606 |doi=10.1016/j.brainres.2011.05.025 |url=}}</ref><ref name="pmid21681607">{{cite journal |vauthors=Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO |title=Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models |journal=Pharmaceutical Research |volume= 28|issue= 10|pages= 2610–27|date=June 2011 |pmid=21681607 |doi=10.1007/s11095-011-0490-x |url=}}</ref> but was discontinued following unsatisfactory trial results.

==See also==
* [[4-Methylpregabalin]]
* [[Gabapentin enacarbil]]
* [[PD-217,014]]

==References==
{{Reflist}}

{{Hypnotics}}
{{Calcium channel blockers}}

[[Category:Abandoned drugs]]
[[Category:Amino acids]]
[[Category:Calcium channel blockers]]
[[Category:GABA analogues]]
[[Category:Hypnotics]]
[[Category:Pfizer]]
[[Category:Cyclopentanes]]


{{sedative-stub}}